Oct 28 (Reuters) - Britain’s GSK said on Wednesday it expects full-year adjusted earnings to be at the lower end of its forecast as the COVID-19 pandemic disrupts vaccination rates, especially for its blockbuster shingles vaccine.
The world’s largest vaccine maker now expects 2020 profit to be at the lower end of its forecast of a 1%-4% drop, which did not include any potential impact from the coronavirus crisis.
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.